• Home
  • Privacy Policy
  • Terms & Conditions
  • Thank you
Profit News Report
No Result
View All Result
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
No Result
View All Result
Profit News Report
No Result
View All Result
Home Investing

C3.ai stock soars on merger news but a takeover is unlikely to rescue it

by
January 29, 2026
in Investing
0
C3.ai stock soars on merger news but a takeover is unlikely to rescue it
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

C3.ai Inc (NYSE: AI) opened about 15% higher today following reports the artificial intelligence firm may soon merge with the privately held “Automation Anywhere”.

Retail investors seem to be believe this deal may prove a turnaround for C3.ai, which has struggled with declining revenue that’s cut its valuation in half over the past year.

Despite today’s rally, C3.ai stock remains down nearly 60% versus its 52-week high.

Why Automation Anywhere’s news doesn’t warrant buying C3.ai stock

Despite initial excitement over a potential tie-up with Automation Anywhere, a closer look reveals this deal may be more of a “bailout” for C3.ai shares than a “breakthrough”.

According to The Information, the privately held company will acquire C3.ai to achieve a reverse-listing, effectively using the ticker as a back-door to the public markets.

This suggests AI’s current shareholders might face significant dilution, given the massive valuation gap between the two: Automation Anywhere was last valued at nearly $6.8 billion, while C3.ai’s market cap has withered to about $1.8 billion only.

Moreover, merging C3.ai’s high-level predictive artificial intelligence with Automation Anywhere’s legacy Robotic Process Automation (RPA) creates immense integration risk.

RPA is often viewed as a “band-aid” for old systems, which stands in stark contrast to C3.ai Inc’s vision of “modernizing” enterprise architecture.

All in all, with C3.ai already struggling with deepening losses and a persistent share price decline, doubling down on a complex, multi-billion-dollar integration could delay any path to profitability and distract from the company’s core “agentic AI” strategy.

C3.ai shares remain a very high-risk proposition for 2026

The fundamental bear case for C3.ai stock rests on a stark contradiction: the company is failing to grow during the greatest secular tailwind in software history.

While the broader AI sector is booming, the NYSE-listed firm’s revenue has entered a period of alarming instability.

In the first half of its fiscal 2026, C3.ai’s revenue plummeted roughly 20% year-over-year, forcing management to withdraw its full-year guidance – a move that typically signals a complete lack of visibility into the sales pipeline.

This “growth reversal” is compounded by a leadership vacuum following the retirement of founder Thomas Siebel, whose personal involvement was critical to closing the company’s signature lumpy multi-million dollar deals.

Financially, the company remains a “cash incinerator”, reporting a staggering GAAP net loss of over $380 million on a trailing twelve-month basis.

Despite an industry-wide push for profitability, C3.ai’s losses have actually widened, with margins squeezed by a pivot to a consumption-based pricing model that has yet to prove its scalability.

Valuation remains another major hurdle; even after a 60% share price collapse in 2025, C3 trades at a premium relative to its peers while delivering vastly inferior growth.  

With intense competition from better-capitalized rivals like Palantir and cloud giants providing their own native AI layers, C3.ai risks becoming a “zombie” stock – possessing the right name and ticker, but lacking the operational muscle to survive the consolidation of the enterprise AI market.

The post C3.ai stock soars on merger news but a takeover is unlikely to rescue it appeared first on Invezz

Previous Post

US stocks open in the green: S&P breaches 7,000, Nasdaq climbs 0.7%

Next Post

ASML stock: buybacks and dividends grab attention, but real signal lies elsewhere

Next Post
Starbucks earnings point to demand recovery, margin headwinds

Starbucks earnings point to demand recovery, margin headwinds

  • Trending
  • Comments
  • Latest
Trump’s Fed Criticism Sparks Investor Concerns

Trump’s Fed Criticism Sparks Investor Concerns

April 22, 2025
A look back at Biden’s Remarkable 50-year career in politics

A look back at Biden’s Remarkable 50-year career in politics

March 20, 2025
Fed’s Stagflation Warning Impacts Crypto Markets

Fed’s Stagflation Warning Impacts Crypto Markets

April 21, 2025
Spire Healthcare shares surge 20% after confirming talks with buyout firms

Spire Healthcare shares surge 20% after confirming talks with buyout firms

January 27, 2026
Trump, Netanyahu to meet at White House in high-stakes talks on Iran, Gaza plan

Trump, Netanyahu to meet at White House in high-stakes talks on Iran, Gaza plan

0
Nvidia Stock Tumbles on Earnings Anticipation and AI Rivalry

Nvidia Stock Tumbles on Earnings Anticipation and AI Rivalry

0
The dollar index continues to pull back to a new low

The dollar index continues to pull back to a new low

0
BNGO Stock: BioNano Genomics Analysis and Forecast

BNGO Stock: BioNano Genomics Analysis and Forecast

0
Trump, Netanyahu to meet at White House in high-stakes talks on Iran, Gaza plan

Trump, Netanyahu to meet at White House in high-stakes talks on Iran, Gaza plan

February 11, 2026
FDA refuses to review Moderna’s mRNA flu vaccine application

FDA refuses to review Moderna’s mRNA flu vaccine application

February 11, 2026
US futures steady as retail sales, jobs and CPI data take center stage

US futures steady as retail sales, jobs and CPI data take center stage

February 11, 2026
Coca-Cola stock slumps as Q4 revenue misses estimates

Coca-Cola stock slumps as Q4 revenue misses estimates

February 11, 2026

Recent News

Trump, Netanyahu to meet at White House in high-stakes talks on Iran, Gaza plan

Trump, Netanyahu to meet at White House in high-stakes talks on Iran, Gaza plan

February 11, 2026
FDA refuses to review Moderna’s mRNA flu vaccine application

FDA refuses to review Moderna’s mRNA flu vaccine application

February 11, 2026
US futures steady as retail sales, jobs and CPI data take center stage

US futures steady as retail sales, jobs and CPI data take center stage

February 11, 2026
Coca-Cola stock slumps as Q4 revenue misses estimates

Coca-Cola stock slumps as Q4 revenue misses estimates

February 11, 2026
  • Privacy Policy
  • Terms & Conditions
  • Privacy Policy
  • Terms & Conditions

Disclaimer: Profitnewsreport.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Copyright © 2025 Profitnewsreport.com

No Result
View All Result
  • Home
  • Privacy Policy
  • Terms & Conditions
  • Thank you

Disclaimer: Profitnewsreport.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Copyright © 2025 Profitnewsreport.com